Objective To explore the feasibility and to improve the efficiency of testing circulating tumor cells(CTC)in patients with renal cell carcinoma by Cell-search System(CSS).Methods Eight patients with renal cell carcinoma hospitalized in the PUMC urology department for further clinical evaluation in Jan.to Jun.2012 were enrolled in this study.There were 5 males and 3 females with mean age of 64 (57-70)years.There were 2 cases in clinical stage T3N0M0 and 6 cases in T4N0M1;3 cases were treated with radical nephrectomy,5 cases were treated with targeted therapy drugs.7.5 ml peripheral blood samples from these patients were collected and saved in test tube at the temperature of 15 ℃-30 ℃.The tests had to be done within 96 hrs after the blood sample drawn.We selected fluorescent anti-CKS/18/19 antibodies as CTC makers for renal cell carcinoma.Then the number of CTC was quantitative detected by CSS.The feasibility and detection rate of testing CTC in patients with RCC by CSS was evaluated,and the improvement of method was discussed.Results Quantitative test results of CTC in 8 patients with renal cell carcinoma were negative.25 CK+CD45 + double positive cells were found in one T4N0M1 patient's peripheral blood.The detection rate of the CTC in TNM stage T3N0M0 and T4N0M1 renal cell carcinoma patients using CSS with epithelial tumor cell maker anti-CK8/18/19 was zero.Conclusions Anti-CK8/18/19 antibodies can not be used in testing circulating tumor cells in patients with renal cell carcinoma by Cell-search System.

Objective: To evaluate the prognostic value of the thrombolysis in myocardial infarction (TIMI) and global registry of acute coronary events (GRACE) risk scores for in-hospital mortality in Chinese non-ST-segment elevation myocardial infarction (NSTEMI) patients. Methods: Data of present study derived from the prospective, multi-center registry trial of Chinese AMI (CAMI). Among 31 provinces, municipalities or autonomous districts in China, at least one tertiary and secondary hospital was selected. From January 2013 to September 2014, 5 896 consecutive non-ST-segment elevation myocardial infarction patients who were admitted to 107 hospitals within 7 days of symptom onset were enrolled. For each patient, TIMI and GRACE risk scores were calculated using specific variables collected at admission. Their prognostic value was evaluated by the endpoint of in-hospital mortality. Results: Among 5 896 NSTEMI patients (age was (65.4±12.1) years old), 68.2% (n=4 020) were males. The in-hospital mortality was 6.0% (n=353) and the median length of hospital stay was 10.0 (7.0, 13.0) days. The incidence of pre-hospital cardiac arrest was 3.6% (n=213) among 5 896 NSTEMI patients. Six hundreds and forty five patients (10.9%) received primary percutaneous coronary intervention, and 6 patients underwent emergent coronary artery bypass grafting surgery (0.1%), and the median time of reperfusion was 529.5 (256.0, 1 065.0) minutes. The prescription percentage of statins, β-blocker, angiotensin converting enzyme inhibitors or angiotensin Ⅱ receptor blockers, and aldosterone antagonists were 94.8% (n=5 587), 71.7% (n=4 228), 65.5% (n=3 864) and 26.0% (n=1 533) respectively. The area under the curve of GRACE risk score for in-hospital mortality (0.7930 (95%CI 0.767-0.818)) was better than that of TIMI risk score (0.5588 (95%CI 0.532-0.586), P<0.001). Conclusion GRACE risk score demonstrates better predictive accuracy than TIMI risk score for in-hospital mortality in NSTEMI patients in this patient cohort.